CD20 — Drug Target
All drugs that target CD20 — marketed and clinical-stage. Includes 23 drug classes acting on this target.
Drug classes
Monoclonal antibody (anti-CD20) · Anti-CD20 monoclonal antibody · CD20-targeting monoclonal antibody · Radioimmunotherapy agent; anti-CD20 monoclonal antibody · Monoclonal antibody · Monoclonal antibody + chemotherapy combination · Radiolabeled monoclonal antibody (anti-CD20) · Chemoimmunotherapy regimen · Monoclonal antibody and chemotherapy regimen · Monoclonal antibody, chemotherapy · Monoclonal antibody (CD20 inhibitor) · Corticosteroid + Monoclonal antibody
Marketed (11)
- RiTUXimab Injection [Truxima] · Laida Cuevas Palomares · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - Kesimpta · Novartis · Anti-CD20 monoclonal antibody · Immunology
Ofatumumab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. - Rituximab (R) · National Cancer Institute (NCI) · CD20-targeting monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - Ibritumomab Tiuxetan (Zevalin) · M.D. Anderson Cancer Center · Radioimmunotherapy agent; anti-CD20 monoclonal antibody · Oncology
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that binds to CD20 on B cells and delivers yttrium-90 radiation directly to tumor cells. - Rituximab 375 · University Hospital, Toulouse · CD20-targeting monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - Standard dose of rituximab · Second Affiliated Hospital, School of Medicine, Zhejiang University · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - Treatment plan · Fondazione Italiana Linfomi - ETS · Monoclonal antibody · Oncology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Rituximab infusion · Centre Hospitalier Universitaire de Saint Etienne · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - R-combination chemotherapy · Shandong Provincial Hospital · Monoclonal antibody + chemotherapy combination · Oncology
R-combination chemotherapy uses rituximab (a monoclonal antibody targeting CD20) combined with cytotoxic chemotherapy agents to kill B-cell malignancies. - rituximab [MabThera/Rituxan] · Hoffmann-La Roche · CD20-targeting monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - MabThera · Sandoz · CD20-targeting monoclonal antibody · Oncology, Immunology
MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Phase 3 pipeline (58)
- Additional doses of Rituximab · University Hospital Muenster · Monoclonal antibody (anti-CD20) · Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. - Ibritumomab Tiuxetan + Maintenance · Fondazione Italiana Linfomi - ETS · Radiolabeled monoclonal antibody (anti-CD20) · Oncology
Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells. - R-FM · Fondazione Italiana Linfomi - ETS · Chemoimmunotherapy regimen · Oncology
R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas. - Rituximab plus CHOP · Sinocelltech Ltd. · Monoclonal antibody and chemotherapy regimen · Oncology
Rituximab targets CD20 on B cells, while CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a chemotherapy regimen. - R-pola-mini-CHP · Nordic Lymphoma Group · Monoclonal antibody + chemotherapy combination · Oncology
R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity. - Ocrelizumab Injection [Ocrevus] · Fondation Ophtalmologique Adolphe de Rothschild · CD20-targeting monoclonal antibody · Immunology / Neurology
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination. - RITUXIMAB + DHAP · GlaxoSmithKline · Monoclonal antibody, chemotherapy · Oncology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while DHAP is a chemotherapy regimen that includes the drugs dexamethasone, high-dose cytarabine, and cisplatin. - Arm B: Rituxan®/Mabthera® · Dr. Reddy's Laboratories Limited · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. - Rituximab (Mabthera) · Shereen Medhat Mohammed Elsayed Nassar · Monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Rituxan +CHOP · Shandong New Time Pharmaceutical Co., LTD · Monoclonal antibody · Oncology
Rituxan is a monoclonal antibody that targets and depletes CD20-positive B cells, while CHOP is a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine, and prednisone. - immunomodulatory treatment by rituximab · University Hospital, Bordeaux · Monoclonal antibody · Immunology
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation. - Ocrelizumab SC · Hoffmann-La Roche · CD20-targeting monoclonal antibody · Immunology
Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells. - Rituximab Monotherapy · Beijing Friendship Hospital · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - Rituximab (EU) · Amgen · Monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Rituximab (Arm A) · Assistance Publique - Hôpitaux de Paris · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - Placebo-rituximab · Assistance Publique - Hôpitaux de Paris · Monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. - EU-Ocrevus · Celltrion · CD20-targeting monoclonal antibody · Immunology
EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. - Rituximab - CVP · The Lymphoma Academic Research Organisation · Monoclonal antibody + chemotherapy combination · Oncology
Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, combined with CVP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to treat lymphoma. - GP2013 - A Proposed biosimilar rituximab · Sandoz · Monoclonal antibody (CD20 inhibitor) · Immunology, Oncology
GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. - prednisolone + mabthera · Copenhagen University Hospital at Herlev · Corticosteroid + Monoclonal antibody · Oncology
Prednisolone is a corticosteroid that suppresses the immune system, while Mabthera (rituximab) is a monoclonal antibody that targets CD20 on B cells. - MabThera/Rituxan · Hoffmann-La Roche · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - Ocrevus-US · Sandoz · Monoclonal antibody · Immunology
Ocrevus-US is a monoclonal antibody that targets CD20 on B cells. - Ocrelizumab Dose 1 · Genentech, Inc. · CD20-targeting monoclonal antibody · Immunology
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation. - rituximab+chlorambucil · International Extranodal Lymphoma Study Group (IELSG) · Monoclonal antibody + alkylating agent · Oncology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication. - Rituximab Biosimilar · Merck Sharp & Dohme LLC · Monoclonal antibody · Oncology
Rituximab Biosimilar works by targeting and depleting CD20-positive B cells. - Rituximab sc · Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH · Monoclonal antibody (anti-CD20) · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. - RTX infusions · Frédéric A. Houssiau, MD, PhD · Monoclonal antibody (B cell depleting agent) · Immunology
RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface. - R-miniCHOP · Universität des Saarlandes · Monoclonal antibody + chemotherapy combination · Oncology
R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity. - R-mini-CHOP · AstraZeneca · Chemotherapy regimen · Oncology
R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone. - Rituximab-HDS · Gruppo Italiano Terapie Innovative nei Linfomi · Monoclonal antibody (anti-CD20) · Oncology
Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen. - US-Ocrevus · Celltrion · Monoclonal antibody (CD20 inhibitor) · Immunology / Oncology
US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation. - Originator rituximab - Rituxan ® or MabThera ® · Sandoz · CD20-targeting monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - R-mNHL-BFM-90 + auto-SCT · National Research Center for Hematology, Russia · Rituximab-based chemotherapy regimen with autologous stem cell transplantation · Oncology
R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue. - Rituximab - CHOP · The Lymphoma Academic Research Organisation · Monoclonal antibody (anti-CD20) · Oncology
Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, used in combination with CHOP chemotherapy to treat lymphomas. - Ocrelizumab (EU) · Amgen · CD20-targeting monoclonal antibody · Immunology
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Ocrelizumab (CinnaGen, Iran) · Cinnagen · CD20-targeting monoclonal antibody · Immunology
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Autologous transplantation using rituxan/BEAM · National Heart, Lung, and Blood Institute (NHLBI) · Monoclonal antibody combined with high-dose chemotherapy and autologous stem cell transplantation · Immunology / Hematology-Oncology
Rituximab depletes B cells, followed by high-dose chemotherapy (BEAM regimen) and autologous stem cell transplantation to reset the immune system. - optimised rituximab-schedule · Universität des Saarlandes · Monoclonal antibody · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. - Ocrelizumab IV · Hoffmann-La Roche · CD20-targeting monoclonal antibody · Immunology
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation. - Ocrevus-EU · Sandoz · CD20-targeting monoclonal antibody · Immunology/Neurology
Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.
Phase 2 pipeline (6)
- BIIB014 · Biogen · Monoclonal antibody · Oncology
BIIB014 is a monoclonal antibody targeting CD20. - Bendamustine and Rituximab · Czech CLL Study Group · Chemotherapy, Monoclonal antibody · Oncology
Bendamustine is a chemotherapy medication that interferes with DNA replication, while Rituximab is a monoclonal antibody that targets and depletes B cells. - Chemotherapy-Rituximab combination · Northern Italy Leukemia Group · Monoclonal antibody · Oncology
Rituximab targets CD20 on B cells - R-CHOP with doxorubicin · Fondazione Italiana Linfomi - ETS · Monoclonal antibody and anthracycline antibiotic · Oncology
Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Abb-R-CHOP · Asan Medical Center · Chemotherapy regimen · Oncology
Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells. - CHOP-R · CTI BioPharma · Chemotherapy regimen · Oncology
CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
Phase 1 pipeline (1)
- ARGX-213 · argenx · Monoclonal antibody · Immunology
Monoclonal antibody targeting CD20